Scientific Advice meetings are a mechanism to improve communications between drug developers and regulators during the drug-development process. While standard practice for industry, the benefits provided by these meetings are under-utilised by academia. In the context of drug repurposing, can scientific advice, as part of a proposed new R&D tax credits scheme, help to unblock some of the obstacles in the way to clinical adoption?
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
IIC - International Review of Intellectual Property and Competition Law Open Access 12 September 2022
Journal of Hematology & Oncology Open Access 18 July 2022
Signal Transduction and Targeted Therapy Open Access 02 July 2020
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Pantziarka, P., Bouche, G., Meheus, L., Sukhatme, V. & Sukhatme, V. P. The Repurposing Drugs in Oncology (ReDO) Project. Ecancermedicalscience 8, 442 (2014).
Bertolini, F., Sukhatme, V. P. & Bouche, G. Drug repurposing in oncology — patient and health systems opportunities. Nat. Rev. Clin. Oncol. 12, 732–742 (2015).
Davies, E. H., Fulton, E., Brook, D. & Hughes, D. A. Affordable orphan drugs: a role for not-for-profit organizations. Br. J. Clin. Pharmacol. http://dx.doi.org/10.1111/bcp.13240 (2017).
UK Parliament. Off-patent Drugs Bill 2015–2016. Parliament.uk http://services.parliament.uk/bills/2015-16/offpatentdrugs.html (2015).
Hadji, P. et al. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European panel. Ann. Oncol. 27, 379–390 (2016).
Pasquier, E. et al. Effective management of advanced angiosarcoma by the synergistic combination of propranolol and vinblastine-based metronomic chemotherapy: a bench to bedside study. EBioMedicine 6, 87–95 (2016).
Chow, W. et al. Growth attenuation of cutaneous angiosarcoma with propranolol-mediated β-blockade. JAMA Dermatol. 151, 1226–1229 (2015).
Regnstrom, J. et al. Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency. Eur. J. Clin. Pharmacol. 66, 39–48 (2010).
Hofer, M. P. et al. Regulatory watch: impact of scientific advice from the European Medicines Agency. Nat. Rev. Drug Discov. 14, 302–303 (2015).
Yordanov, Y. et al. Avoidable waste of research related to inadequate methods in clinical trials. BMJ 350, h809 (2015).
The author declares no competing financial interests.
About this article
Cite this article
Pantziarka, P. Scientific advice — is drug repurposing missing a trick?. Nat Rev Clin Oncol 14, 455–456 (2017). https://doi.org/10.1038/nrclinonc.2017.69
Journal of Hematology & Oncology (2022)
IIC - International Review of Intellectual Property and Competition Law (2022)
Blood Cancer Journal (2020)
Signal Transduction and Targeted Therapy (2020)